Please login to the form below
Former Roche CEO joins BIAL board
Franz Humer to advise Portuguese pharma company
Portugal-based pharma company BIAL has appointed former Roche CEO Franz Humer as a non-executive member of its board.
Humer has vast experience in the pharma industry, spending 10 years as CEO of Swiss giant Roche from 1998 to 2008 and 13 years as chairman of its board of directors from 2001 to 2014 when he retired from the company.
In total he spent 19 years at Roche, where he also served as chief operating officer and head of its pharmaceutical division. This followed 15 years at Glaxo Holdings (now part of GSK) and 8 years at Schering Plough (now part of Merck & Co).
He will now advised BIAL which has a strong presence in southern Europe and in Latin America and is looking to grow internationally.
Luís Portela, chairman of BIAL, said: "It is an honour to count on the experience of Dr Franz Humer, who dedicated his professional career to the pharmaceutical industry in large multinational companies of innovation. His incorporation is especially relevant to BIAL as it is a recognition of the work we have been developing."
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
